摘要
目的 探讨对眩晕患者选择复方归芎胶囊+曲克芦丁脑蛋白水解物进行治疗后获得的临床效果。方法 40例眩晕患者,按照随机数字表法分为参照组与实验组,各20例。参照组拟定曲克芦丁脑蛋白水解物方案展开治疗,实验组拟定复方归芎胶囊+曲克芦丁脑蛋白水解物方案展开治疗。观察对比两组患者的临床疗效;治疗前后右椎动脉(RVA)、左椎动脉(LVA)、基底动脉(BA)平均血流速度;用药安全性。结果 实验组患者治疗总有效率95.00%高于参照组的45.00%,差异具有统计学意义(P<0.05)。治疗后,实验组患者RVA、LVA以及BA平均血流速度分别为(38.35±4.49)、(39.13±5.52)、(40.79±5.69)cm/s,均明显高于参照组的(33.25±4.85)、(33.29±5.03)、(34.13±4.99)cm/s,差异具有统计学意义(P<0.05)。实验组患者用药不良反应发生率10.00%明显低于参照组的40.00%,差异具有统计学意义(P<0.05)。结论 眩晕患者于临床接受复方归芎胶囊+曲克芦丁脑蛋白水解物治疗后,有利于治疗总有效率的升高, RVA、LVA以及BA平均血流速度的增加,安全性的提升,最终促进眩晕患者早期转归。
Objective To discuss the clinical effect of compound Chuanxiong capsule combined with troxerutin brain protein hydrolysate in the treatment of vertigo.Methods A total of 40 vertigo patients were divided into control group and experimental group by random number table method,with 20 cases in each group.The control group was treated by troxerutin brain protein hydrolysate,and the experimental group was treated by compound Chuanxiong capsule combined with troxerutin brain protein hydrolysate.The clinical efficacy,mean blood flow velocity of right vertebral artery(RVA),left vertebral artery(LVA)and basilar artery(BA)before and after treatment,and drug safety were observed and compared between the two groups.Results The total effective rate of treatment 95.00%of the experimental group was higher than that of the control group 45.00%,and the difference was statistically significant(P<0.05).After treatment,the mean blood flow velocity of RVA,LVA and BA of the experimental group were(38.35±4.49),(39.13±5.52)and(40.79±5.69)cm/s,which were obviously higher than those of the control group(33.25±4.85),(33.29±5.03)and(34.13±4.99)cm/s,and the difference was statistically significant(P<0.05).The incidence of adverse drug reactions 10.00%of the experimental group was obviously lower than that of the control group 40.00%,and the difference was statistically significant(P<0.05).Conclusion Compound Chuanxiong capsule combined with troxerutin brain protein hydrolysate can improve the total effective rate,RVA level,LVA level,BA level and safety,and ultimately promote the early prognosis of vertigo patients.
作者
李苑红
刘民胜
胡冬蓉
LI Yuan-hong;LIU Min-sheng;HU Dong-rong(Meizhou Hospital of Traditional Chinese Medicine,Meizhou 514000,China)
出处
《中国现代药物应用》
2020年第10期104-106,共3页
Chinese Journal of Modern Drug Application
基金
梅州市医药卫生科研课题(项目编号:2019-B-70)。
关键词
复方归芎胶囊
曲克芦丁脑蛋白水解物
眩晕
临床疗效
Compound Chuanxiong capsule
Troxerutin brain protein hydrolysate
Vertigo
Clinical efficacy
